{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:59:24Z","timestamp":1782799164651,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01330-9","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:58:58Z","timestamp":1760187538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Do Incretin-Based Therapies Influence the Risk of Cholangiocarcinoma in Type 2 Diabetes Patients? Insights from a Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"56","author":[{"given":"Eric Ricardo","family":"Yonatan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Fabio Jonathan","family":"Jusni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Alvianto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas Daniel","family":"Widjanarko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Yulius","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virly Nanda","family":"Muzellina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"issue":"S1","key":"1330_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(S1):5\u201321. https:\/\/doi.org\/10.1111\/dom.13129.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1330_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819\u201337. https:\/\/doi.org\/10.1016\/j.cmet.2013.04.008.","journal-title":"Cell Metab"},{"key":"1330_CR3","doi-asserted-by":"publisher","first-page":"1130625","DOI":"10.3389\/fmolb.2023.1130625","volume":"10","author":"K Saini","year":"2023","unstructured":"Saini K, Sharma S, Khan Y. DPP-4 inhibitors for treating T2DM - hype or hope? An analysis based on the current literature. Front Mol Biosci. 2023;10:1130625. https:\/\/doi.org\/10.3389\/fmolb.2023.1130625.","journal-title":"Front Mol Biosci"},{"key":"1330_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00178","author":"MP Gilbert","year":"2020","unstructured":"Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol. 2020. https:\/\/doi.org\/10.3389\/fendo.2020.00178.","journal-title":"Front Endocrinol"},{"key":"1330_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4880","author":"D Abrahami","year":"2018","unstructured":"Abrahami D, Douros A, Yin H, Yu OH, Faillie J-L, Montastruc F, et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: Population based Cohort Study. BMJ. 2018. https:\/\/doi.org\/10.1136\/bmj.k4880.","journal-title":"BMJ"},{"key":"1330_CR6","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.34172\/ijdrc.2023.e19","volume":"1","author":"M Oladghaffari","year":"2023","unstructured":"Oladghaffari M, Rahnemayan S, Tohid Z, Montazer M, Dabiri F. Incretin-based therapies and the risk of breast cancer in women with type 2 diabetes mellitus: a systematic review and meta-analysis. Int J Drug Res Clin. 2023;1:e19. https:\/\/doi.org\/10.34172\/ijdrc.2023.e19.","journal-title":"Int J Drug Res Clin"},{"key":"1330_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41598-023-27509-3","volume":"13","author":"A Juji\u0107","year":"2023","unstructured":"Juji\u0107 A, Godina C, Belting M, Melander O, Juul Holst J, Ahlqvist E, et al. Endogenous incretin levels and risk of first incident cancer: a prospective cohort study. Sci Rep. 2023;13:382. https:\/\/doi.org\/10.1038\/s41598-023-27509-3.","journal-title":"Sci Rep"},{"issue":"4","key":"1330_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00592-019-01444-0","volume":"57","author":"CB Giorda","year":"2019","unstructured":"Giorda CB, Picariello R, Tartaglino B, Nada E, Costa G, Gnavi R. Incretin-based therapy and risk of cholangiocarcinoma: a nested case\u2013control study in a population of subjects with type 2 diabetes. Acta Diabetol. 2019;57(4):401\u20138. https:\/\/doi.org\/10.1007\/s00592-019-01444-0.","journal-title":"Acta Diabetol"},{"issue":"10","key":"1330_CR9","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1007\/s00125-021-05508-1","volume":"64","author":"P Ueda","year":"2021","unstructured":"Ueda P, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franz\u00e9n S, et al. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. Diabetologia. 2021;64(10):2204\u201314. https:\/\/doi.org\/10.1007\/s00125-021-05508-1.","journal-title":"Diabetologia"},{"key":"1330_CR10","doi-asserted-by":"publisher","first-page":"100370","DOI":"10.1016\/j.jcte.2024.100370","volume":"38","author":"A Krishnan","year":"2024","unstructured":"Krishnan A, Schneider CV, Arkenau HT, Mauro EM, Forner A, Scott Butsch W, et al. Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: a large population-based matched cohort study. J Clin Transl Endocrinol. 2024;38:100370. https:\/\/doi.org\/10.1016\/j.jcte.2024.100370.","journal-title":"J Clin Transl Endocrinol"},{"key":"1330_CR11","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/medicina61040678","volume":"61","author":"S Medenica","year":"2025","unstructured":"Medenica S, Bogdanovic J, Vekic J, Vojinovic T, Babic I, Bogdanovi\u0107 L, et al. Incretin-based therapies and cancer: what\u2019s new? Medicina (Kaunas). 2025;61:678. https:\/\/doi.org\/10.3390\/medicina61040678.","journal-title":"Medicina (Kaunas)"},{"key":"1330_CR12","doi-asserted-by":"publisher","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","volume":"14","author":"SF Mehdi","year":"2023","unstructured":"Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209. https:\/\/doi.org\/10.3389\/fimmu.2023.1148209.","journal-title":"Front Immunol"},{"key":"1330_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12672-022-00536-8","volume":"13","author":"H Sun","year":"2022","unstructured":"Sun H, Qi X. The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence. Discover Oncol. 2022;13:70. https:\/\/doi.org\/10.1007\/s12672-022-00536-8.","journal-title":"Discover Oncol"},{"issue":"1","key":"1330_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1210\/endrev\/bnac018","volume":"44","author":"JM Yabut","year":"2022","unstructured":"Yabut JM, Drucker DJ. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2022;44(1):14\u201332. https:\/\/doi.org\/10.1210\/endrev\/bnac018.","journal-title":"Endocr Rev"},{"key":"1330_CR15","doi-asserted-by":"publisher","first-page":"e068882","DOI":"10.1136\/bmj-2021-068882","volume":"377","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, Yang N, Huang J, Li W, et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. BMJ. 2022;377:e068882. https:\/\/doi.org\/10.1136\/bmj-2021-068882.","journal-title":"BMJ"},{"key":"1330_CR16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.3390\/cancers13092191","volume":"13","author":"E Kawakita","year":"2021","unstructured":"Kawakita E, Koya D, Kanasaki K. CD26\/DPP-4: type 2 diabetes drug target with potential influence on cancer biology. Cancers (Basel). 2021;13:2191. https:\/\/doi.org\/10.3390\/cancers13092191.","journal-title":"Cancers (Basel)"},{"key":"1330_CR17","doi-asserted-by":"publisher","first-page":"114517","DOI":"10.1016\/j.bcp.2021.114517","volume":"188","author":"R Yazbeck","year":"2021","unstructured":"Yazbeck R, Jaenisch SE, Abbott CA. Dipeptidyl peptidase 4 inhibitors: applications in innate immunity? Biochem Pharmacol. 2021;188:114517. https:\/\/doi.org\/10.1016\/j.bcp.2021.114517.","journal-title":"Biochem Pharmacol"},{"key":"1330_CR18","doi-asserted-by":"publisher","unstructured":"Barreira da Silva R, Laird ME, Yatim N, Fiette L, Ingersoll MA, Albert ML. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol. 2015;16(8):850\u20138. https:\/\/doi.org\/10.1038\/ni.3201","DOI":"10.1038\/ni.3201"},{"key":"1330_CR19","doi-asserted-by":"publisher","first-page":"108304","DOI":"10.1016\/j.ejso.2024.108304","volume":"51","author":"O McGreevy","year":"2025","unstructured":"McGreevy O, Bosakhar M, Gilbert T, Quinn M, Fenwick S, Malik H, et al. The importance of preclinical models in cholangiocarcinoma. Eur J Surg Oncol. 2025;51:108304. https:\/\/doi.org\/10.1016\/j.ejso.2024.108304.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"1330_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5009\/gnl15568","volume":"11","author":"B Blechacz","year":"2017","unstructured":"Blechacz B. Cholangiocarcinoma: current knowledge and new developments. Gut Liver. 2017;11(1):13\u201326. https:\/\/doi.org\/10.5009\/gnl15568.","journal-title":"Gut Liver"},{"issue":"2","key":"1330_CR21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2337\/dc17-0280","volume":"41","author":"M Boniol","year":"2017","unstructured":"Boniol M, Franchi M, Bota M, Leclercq A, Guillaume J, van Damme N, et al. Incretin-based therapies and the short-term risk of pancreatic cancer: results from two retrospective cohort studies. Diabetes Care. 2017;41(2):286\u201392. https:\/\/doi.org\/10.2337\/dc17-0280.","journal-title":"Diabetes Care"},{"key":"1330_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305","author":"L Wang","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21305.","journal-title":"JAMA Netw Open"},{"issue":"25","key":"1330_CR23","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.3748\/wjg.v28.i25.2881","volume":"28","author":"V Suryadevara","year":"2022","unstructured":"Suryadevara V, Roy A, Sahoo J, Kamalanathan S, Naik D, Mohan P, et al. Incretin based therapy and pancreatic cancer: realising the reality. World J Gastroenterol. 2022;28(25):2881\u20139. https:\/\/doi.org\/10.3748\/wjg.v28.i25.2881.","journal-title":"World J Gastroenterol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01330-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01330-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01330-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:58:59Z","timestamp":1760187539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01330-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01330-9","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"5 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"198"}}